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Abstract
The relationship between peroxisome proliferator-activated receptor c (PPARG) expression and epigenetic changes
occurring in colorectal-cancer pathogenesis is largely unknown. We investigated whether PPARG is epigenetically regulated
in colorectal cancer (CRC) progression. PPARG expression was assessed in CRC tissues and paired normal mucosa by western
blot and immunohistochemistry and related to patients’ clinicopathological parameters and survival. PPARG promoter
methylation was analyzed by methylation-specific-PCR and bisulphite sequencing. PPARG expression and promoter
methylation were similarly examined also in CRC derived cell lines. Chromatin immunoprecipitation in basal conditions and
after epigenetic treatment was performed along with knocking-down experiments of putative regulatory factors. Gene
expression was monitored by immunoblotting and functional assays of cell proliferation and invasiveness. Methylation on a
specific region of the promoter is strongly correlated with PPARG lack of expression in 30% of primary CRCs and with
patients’ poor prognosis. Remarkably, the same methylation pattern is found in PPARG-negative CRC cell lines. Epigenetic
treatment with 59-aza-29-deoxycytidine can revert this condition and, in combination with trichostatin A, dramatically re-
activates gene transcription and receptor activity. Transcriptional silencing is due to the recruitment of MeCP2, HDAC1 and
EZH2 that impart repressive chromatin signatures determining an increased cell proliferative and invasive potential, features
that can experimentally be reverted. Our findings provide a novel mechanistic insight into epigenetic silencing of PPARG in
CRC that may be relevant as a prognostic marker of tumor progression.
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Introduction
Peroxisome Proliferator-Activated Receptors (PPARs) are
ligand-dependent transcription factors belonging to the nuclear
hormone receptor superfamily [1]. Three different PPAR
isoforms, a, b and c have been isolated so far, each with a
distinct pattern of tissue expression and ability to interact with
diverse classes of compounds. Specifically, the PPARc isoform is
implicated in a wide range of physiological processes [2]: it
integrates the control of energy, lipid and glucose homeostasis and
plays a pivotal role in adipogenesis, inflammatory response and
differentiation of many epithelial cells [3]. Consistently, variations
in PPARG expression or gene mutations have been associated with
tumorigenesis [4–6]. However, conflicting results have been
reported so far, raising the question as to whether PPARc
facilitates or suppresses tumorigenesis [7,8]. Recently, we have
shown that sporadic colorectal cancers (CRCs) presenting reduced
PPARc expression levels are significantly associated with patients’
worse prognosis; in the same type of tumours, PPARG has been
shown to be an independent prognostic factor [9,10], suggesting
the possibility to target this gene with drugs in clinical applications
[10]. The molecular mechanisms underlying PPARG expression
regulation in CRC progression are still unknown [9].
It is becoming increasingly clear that, in addition to genetic
alterations, epigenetic modifications contribute to tumorigenesis
[11]. Epigenetic regulation involves heritable modifications that do
not change the DNA sequences but provide ‘‘extra’’ layers of
control to regulate chromatin organization and gene expression
[12]. Aberrant DNA methylation at CpG-rich sequences, also
known as ‘‘CpG islands’’, located in the promoter regions of
approximately half of the known genes, leads to epigenetic silencing
of gene expression [11,12]. In CRC, extensive DNA methylation
has been detected at several loci, specifically at the promoter regions
of tumor suppressor genes (TSG), a characteristic of a subgroup of
tumours presenting the so-called ‘‘CpG island methylator pheno-
type’’ (CIMP) [13]. Other epigenetic events, such as repressive
histone modifications, cooperate to establish stable gene silencing. A
‘‘histone code’’ has been suggested to provide a signature on specific
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expression [11,12]. The link betweenDNA methylationand histone
modifications seems to be mediated by Methyl CpG DNA binding
proteins, a member of which MeCP2 plays an important role to
establish this interaction [14]. DNA methylated regions, usually
enriched in modified histones, generate a more tightly packed
chromatin where the access of specific transcription factors to their
cognate binding sites is greatly impaired [12]. How DNA
methylation and the pattern of histone modifications on promoter
regions of specific genes are associated with cancer initiation and
progression, in particular in sporadic CRC, remains to be
elucidated [15]. In this report, we analyzed one-hundred and
fifty-two primary CRCs and paired normal mucosa in order to
correlate PPARG expression variations mediated by epigenetic
events with tumor progression and patients’ survival. We extended
the analysis to CRC derived cell lines as a system to investigate the
molecular mechanisms underlying PPARG silencing due to
epigenetic variations.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Fatebenefratelli Hospital in
Benevento. All patients provided written informed consent for
the collection of samples and subsequent analysis.
Tumor samples
One hundred and fifty-two patients diagnosed primary sporadic
CRC and surgically treated at the Department of Surgery,
Fatebenefratelli Hospital, Benevento, Italy, between 1999–2004,
were investigated in this study. Fifty-two cases comprise both
liquid nitrogen snap-frozen specimens, obtained immediately after
surgical resection, and paraffin blocks. Each sample was matched
with the adjacent apparently normal mucosa (at 20 cm distance
from the tumor mass) removed during the same surgery. None of
the patients had a familial history of intestinal dysfunction or
CRC, had received chemotherapy or radiation prior to resection
nor had taken non steroidal anti-inflammatory drugs on a regular
basis. Conventional postoperative treatments were provided to all
patients, depending upon the severity of the disease. The clinico-
pathological features of the patients investigated are reported
(Table 1). The follow-up was available for all patients, with a
median post-operative duration of 59.5626.5 months. Overall
length of survival was calculated starting from the first surgery.
Patients were prospectively followed until death or their most
recent medical examination.
Cell lines and 59-aza-29-deoxycytidine and Trichostatin A
treatment
Twelve CRC derived cell lines were used in this study and were
obtained from the ATCC and cultured as suggested. For DNA
demethylation, cells were treated with 1 or 5 mM5 9-aza-29-
deoxycytidine (AZA) for 72 hs or 300 nM Trichostatin A (TSA)
(Sigma-Aldrich, St. Louis, USA) for 24 hs, alone or in combina-
tion. After the treatments, cells were harvested for DNA, RNA or
protein extraction.
DNA extraction, bisulphite treatment, methylation
analysis and sequencing
Genomic DNA was isolated from frozen tissues or from paraffin
embedded samples using a standard procedure [6], or the FFPE
tissue kit (56404, Qiagen, Hilden, Germany), respectively. One mg
of each DNA sample was bisulphite modified according to the
manufacturer’s protocol (59104, Qiagen, Hilden, Germany). Both
universally unmethylated (59665) and CpGenome universally
methylated DNA (59655, Qiagen, Hilden, Germany) were used in
each reaction as unmethylated or methylated control, respectively.
The search for CpG content in the PPARG promoter was
Table 1. Correlation between PPARG promoter methylation
and several clinico- pathological parameters of the patients.
Parameters N M3 PPARG methylation P
Met Umet
Gender 0.719
Male 95 31 64
Female 57 17 40
Age(Years) 0.001**
#60 32 18 14
.60 120 30 90
Location
a 0.230
Proximal 56 21 35
Distal 96 27 69
Tumor size 0.683
#5c m 5 1 1 5 3 6
.5 cm 101 33 68
Differentiation 0.069
Well/Mod 129 37 92
Por 23 11 12
Histology
b 0.110
AD 123 36 87
AD-MUC 26 10 16
MUC 3 2 1
T stage 0.05*
pT1 9 2 7
pT2 12 5 7
pT3 125 37 88
pT4 6 4 2
N stage 0.002**
N0 111 26 85
N1 25 14 11
N2 16 8 8
Distant Metastasis 0.0001**
M0 107 23 84
M1 45 25 20
Total 152 48 104
aProximal: caecum, ascending and transverse colon; Distal: descending and
sigmoid colon, rectum;
bAD = adenocarcinoma; AD-MUC= adenocarcinoma with a mucinous
component below 50%; MUC= adenocarcinoma with a mucinous component
above 50%. Abbreviations: Well=well-differentiated; Mod=moderately
differentiated; Por=poorly differentiated adenocarcinoma. x
2 test;
*Significant at 0.05 level;
**Significant at 0.01 level. Patients’ mean age was 71.1612.3 years old. The
classification of the tumours was based on the TNM (Tumor-Node-Metastasis)
system according to the criteria of the International Union Against Cancer
(UICC).
doi:10.1371/journal.pone.0014229.t001
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island definition. PCR primers for methylation specific PCR (MS-
PCR) were designed using Methyl Primer Express software v1.
Both unmethylated (U) and methylated (M) specific sets of primers
were designed based on the positive strand of the bisulfite-
converted DNA covering the CpG islands within the PPARG
promoter region. MS-PCR reactions were performed using the
MS-PCR kit (59305, Qiagen, Hilden, Germany) following the
manufacturer’s instructions. PCR products were loaded onto non-
denaturing 3% agarose gels, stained with ethidium bromide, and
visualized under an UV transilluminator. Primer sequences are
listed (Table S1). Bisulphite sequencing (BS) was automatically
carried out on the PCR amplification product obtained by using a
primer set not containing CpG sites within their sequences and
designed on bisulphite modified DNA (Applied Biosystems,
Applera, Foster City, USA).
ChIP and MeDIP assay
ChIP assays and q-PCR amplification (Biorad, Hercules, USA)
were performed as described [16]. The primers used are described
(Table S1). MeDIP assay was carried out as recommended by the
supplier (Diagenode, Lie `ge, Belgium). Antibodies raised against:
AcH3K9, H3K4me3, HDAC1 and MeCP2 (Abcam, Cambridge,
UK), H3K27me3, (Millipore, Billerica, USA), RNA pol II and P-
RNA pol II (Covance, Dallas, USA), ZAC and purified IgG (Santa
Cruz Biotechnology, Santa Cruz, USA) were used in ChIP assays.
Western blot and immunohistochemical analysis
Western blot analysis was performed on protein extracts from
tumor tissues and adjacent normal mucosa taken during surgery
and CRC cell lines, as previously reported [6,9]. Immunohisto-
chemical analysis on tumors and distant non-neoplastic mucosa
was performed as described [9]. The following antibodies were
used: anti-PPARc (E-8), anti-ZAC (H-253), anti-ERK 1/2 (MK1)
and anti-p-ERK (E-4) (Santa Cruz Biotechnology, Santa Cruz,
USA); anti-E-cadherin (610405) (BD Transduction Laboratories,
Lexington, USA); anti-MeCP2 (ab55538), anti-HDAC1 (ab19845)
(Abcam, Cambridge, UK); anti-EZH2 (4905) (Cell Signaling,
Boston, USA); anti-b-actin (A5441) (Sigma-Aldrich, St. Louis,
USA).
MTT and apoptosis assays
Cells were seeded in triplicate in 24 or 96 well-plates and the
MTT assay (Sigma-Aldrich, St. Louis, USA) was performed
according to the manufacturer’s protocol at 0, 24, 48, 72 and
96 hs after reaching confluence, as indicated. The growth curves
were set up taking into account the average results obtained from
three independent experiments. To analyze chemo-sensitivity to
PPARc agonists cells were treated with 5 mM troglitazone (TZD).
Apoptosis assay was performed by flow cytometric analysis (FCA)
using propidium iodide (PI) staining. Briefly, after incubation with
TZD, cells were harvested and fixed in 70% ice-cold ethanol/PBS
and stored at 4uC overnight. The suspended cells were then
washed with PBS, incubated in a PI solution for 15 min. at 37uC
and immediately analyzed with a FAC scan flow cytometer
(Becton Dichinson, San Jose, USA).
Migration and invasion assays
For the wound-healing assay, cells were plated in 60-mm plates
and grown to confluence. After a 6 hs long serum starvation, a
wound was made by using a micropipette tip to scrape off the cells.
Cell motility was studied after 24 and 48 hs, following cells from
different microscope fields. Finally, the corresponding wound area
at each time point was digitalized and quantified using
Metamorph Imaging System Software version 6.0 for Microsoft
Windows. An average percentage of wound closure was calculated
from three independent experiments. To determine invasiveness a
transwell assay was carried out using a 24 well cell culture insert,
8 mm pore (3097, Falcon-Becton Dickinson, USA). Following
hydration of the matrigel in the upper compartment, cells were
seeded and incubated. Twenty-four and forty-eight hs later the
cells of the upper surface of the filter were removed with a cotton
swab; those underneath were fixed with 4% paraformaldehyde,
stained with 0,2% crystal violet and counted. Quantification was
obtained by counting at least 10 lower power fields from three
independent experiments.
RNA extraction and semi-quantitative reverse
transcription-PCR
Total RNA was isolated from cell lines and tissues with Trizol
with minor modifications (Invitrogen Carlsbad, USA). Reverse
transcription-PCR (RT-PCR) was made using Super-script II
(Invitrogen, Carlsbad, USA) and PCR amplification using specific
primers for PPARG. The RT-PCR conditions and the primers
used have previously been reported [5]. In all PCR reactions,
GAPDH served as an internal control for normalization. The
amplified products were run on a 2% agarose gel and stained with
ethidium bromide.
Plasmids and transfections
The PPRE-TK driven luciferase reporter plasmid, the pcDNA3
carrying the wild type PPARG cDNA and the transfection
conditions have already been described [6]. For gene re-activation
assays, cells were seeded in 6-well plates, treated with AZA and
TSA alone or in combination and transiently transfected with the
reporter plasmid. After 12 hs, 1 mM TZD or the vehicle alone
were added to the medium. When indicated, GW9662, a selective
PPARc antagonist, was used.
siRNA
A retroviral vector PSM2C (clone ID VH2-203345) that carries
a short hairpin DNA (shRNA, catalog number RHS1764-
9494331) for targeting PPARc mRNA was used. HT29 cells were
stably transfected with the shRNA-PPARc vector and the positive
clones selected by using 1 mM puromycin. A vector carrying non-
specific shRNAs or an empty vector were used as controls. The
siRNA designed for targeting human MeCP2 mRNA (code: HS-
MECP2-7HP SI02664893, Qiagen, Hilden, Germany) was kindly
provided by Prof. Chiariotti. HCT116 cells were seeded in 6-well
plates and transiently transfected with the MeCP2 siRNA or non-
specific oligos, according to the manufacturer’s instructions
(Invitrogen, Carlsbad, USA). To silence EZH2, a retroviral vector
PSM2C carrying an EZH2-shRNA (code: RHS1764-9100483,
CN: V2HS-63033) scrambled shRNAs or an empty vector were
used, according to the manufacturer’s instructions (Invitrogen,
Carlsbad, USA). In both cases, cells were harvested for western
blot analysis 56 hs later.
Loss of heterozygosity, BRAF and KRAS mutations and
microsatellite instability analysis
Loss of heterozygosity (LOH) was assessed as previously
described, using the microsatellite markers D31259 and
D3S3701, which flank PPARG [6]. Microsatellite instability
(MSI) was performed as reported [17]. MLH1 promoter
methylation was also assessed on some representative tumour
samples [18]. BRAF and KRAS mutations at codon 600 in exon 15
PPAR c in CRC
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PCR/sequencing and Real-Time PCR using primers previously
described [18].
Statistical analysis
All statistical analyses were carried out with the SPSS (version
15.0) for Windows (SPSS Inc., Chicago, USA). Association
between PPARG promoter methylation, other markers and
clinico-pathological parameters was assessed using the x
2 test or
the Spearman rank test, as indicated. The Kaplan-Meier method
was used to estimate survival; survival differences were analyzed
with the log-rank test. Data were reported as mean 6 SD, and
mean values were compared using the Student’s t test or Mann-
Whitney test. Results were considered statistically significant when
a P#0.05 was obtained.
Results
PPARG promoter methylation in CRCs correlates with
gene expression and is associated with patients’
outcome
To assess the role that PPARG plays in colorectal tumorigenesis
in vivo, we analyzed 152 primary sporadic CRCs and the matched
adjacent non-neoplastic mucosa for PPARG expression (Figure 1,
panel A). About 60% of tumors showed PPARG over-expression
and 5% of cases showed not significant differences between
tumour tissues and the matched normal mucosa. In contrast, 35%
of the tumours showed lower PPARc levels than the normal
mucosa and a significant association with distant metastases and
reduced patients’ survival, in line with our previous data
(Figure 1, panels B and C) [9]. We have already reported
that reduced PPARG expression in sporadic CRCs is not associated
with LOH [6]. Thus, to determine whether PPARG reduced
expression is correlated with DNA methylation, we examined the
entire promoter region. Inspection of the human PPARG promoter
showed that the core region, from 2474 to +600 with respect to
the transcription start site, is particularly enriched in ‘‘CpG
islands’’ that might be target of DNA methylation (Figure 1,
panel D). A shorter CpG-rich DNA tract located upstream (from
2793 to 2580) has been found stably methylated in a study
evaluating the epigenetic risk factor associated with the early onset
of adult metabolic syndrome (Figure 1, panel D) [19]. To
investigate whether these two regions are differentially methylated
in primary CRCs and paired normal mucosa, we performed MS-
PCR on four promoter segments (M1 to M4 starting from the
more downstream) (Figure 1, panel D). Segments M4
(from2746 to 2616) and M1 (from 2123 to +49) were always
methylated or unmethylated in normal and tumor samples and
were not correlated with PPARG expression levels (Figure 1,
panel E). M2 (from 2235 to 2151) was variably methylated and,
finally, M3 (from 2359 to 2260) was methylated in about 30% of
tumours as compared to 8% of paired normal mucosas (n=80)
and correlated with reduction/loss of PPARG expression
(Figure 1, panel E and Table 1). A closer inspection of the
M3 segment identified 9 CpG sites, the methylation status of
which was analyzed by bisulphite sequencing (Figure 1, panel
F). The CpG islands methylation level was significantly higher in
PPARG-negative than PPARG-positive tumours and paired normal
mucosas (Figure 1, panel G). Consistently, the M3 region
methylation correlated with patient’s age, deep invasion, Duke’s C
and D stages, whereas no association was detected with tumour
location (proximal or distal colon) and gender (Figure 1, panel
H and Table 1). PPARG methylation was more frequently
observed in a subgroup of microsatellite high (MSI-H) than in
microsatellite stable (MSS) tumours. Moreover, these cases were
not related with KRAS or BRAF mutations (Figure S1). All
together these results indicate that PPARG promoter methylation,
specifically at the M3 region, is significantly correlated with
tumour progression and patients’ poor outcome (Figure 1,
panel I).
PPARG silencing in CRC cell lines correlates with
promoter methylation
To investigate the molecular mechanism(s) underlying this
relationship, we sought to use an in vitro cell culture system. We
screened a series of human CRC cell lines (Table S2) for PPARG
expression levels and correlated these with possible silencing
events. PPARc expression was investigated at the mRNA and
protein level by RT-PCR and western blot analysis, respectively
(Figure 2, panel A). PPARc mRNA mirrored protein levels with
a wide range of variations from the highest in HT29 to the lowest
in HCT116 cells. The differences detected were attributed to
transcription variations; a reduced protein expression not related
to mRNA levels was observed only in Caco-2 cells, likely due to
post-translational mechanism(s). Among these cell lines, we
selected HT29 and HCT116 for further investigations. We did
not detect loss of heterozygosity at the PPARG locus in both cell
lines. Similarly, we did not correlate the different PPARG levels
observed in HCT116 and HT29 cells with post-translational
modifications caused by an active mitogen-activated protein kinase
(MAPK/ERK) pathway (Figure S2) [6,20]. To investigate
whether PPARG expression correlates with promoter methylation
in the CRC cell lines, we performed MS-PCR (Figure 2, panel
B). The M4 and M1 segments were stably methylated or
unmethylated in all cell lines, regardless of PPARc expression.
The M2 segment was methylated in 5 out of 8 cell lines, including
HCT116. Interestingly, the M3 segment was methylated only in
HCT116 out of the eight CRC cell lines analyzed (Figure 2,
panel B). By examining four additional CRC cell lines, we found
that also RKO cells were negative for PPARG expression, due to
aberrantly methylated M3 region (Table S2 and data not
shown). MeDIP assays confirmed these results: the PPARG
promoter DNA (from 2368 to 2166) was three-fold more
methylated in HCT116 than in HT29 cells, indicating a more
tightly packed chromatin structure (Figure S2). 90% of the CpG
sites contained in the M3 segment were methylated in HCT116,
whereas only few or none were methylated in other cell lines as
assessed by bisulphite sequencing (Figure 2, panel C). These
findings suggest that promoter methylation could play a role in
silencing PPARG expression in the CRC cell lines analyzed.
PPARG expression is re-activated by pharmacologic
demethylation
To verify whether PPARG expression can be re-activated by
pharmacologic demethylation, we treated HCT116 cells with
AZA, a well-known inhibitor of DNA methylation. RT-PCR
analysis from HCT116 exposed to 1 and 5 mM AZA showed a
dose-dependent increase of the PPARc mRNA whereas did not
show significant variations in HT29 cells, as expected (Figure 2,
panel D). MS-PCR performed on the M3 region, that is
methylated only in HCT116 cells, showed loss of methylation
following the treatment; the M2 region, that in basal conditions is
methylated in both cell lines, got demethylated after the treatment
(Figure 2, panel D). All together these data demonstrate that
extensive promoter methylation is associated with reduced PPARG
expression in CRC cell lines.
PPAR c in CRC
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total protein extracts from tumour tissues (T) and matched non-neoplastic mucosa (N) were analyzed by Western blot. In the panel only some
representative samples (from 1 to 8) are shown. The histogram reports the quantification to b-actin, used as internal control. (B) Correlation of PPARG
PPAR c in CRC
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14229Co-operative effect of AZA and TSA on PPARG re-
activation
That specific regions of the PPARG promoter are differentially
methylated points out that epigenetic mechanism(s) are involved in
its deregulated expression in CRC cells. To verify this hypothesis,
we treated HCT116 with AZA, alone or in combination with
TSA, a known histone deacetylase inhibitor (HDACi). HT29 cells
were used as a control. PPARG expression was synergistically
induced by the combined treatment with AZA and TSA in
HCT116 cells while was not affected in HT29 cells, when the
drugs were used either alone or in combination (Figure S3).
These data indicate that chromatin-associated histone enzymes
may contribute to gene silencing. To determine whether the re-
activated PPARc behaves as a bona fide functional transcriptional
factor, we treated HCT116 cells with AZA or TSA alone or in
combination and subsequently transfected with a PPRE-driven
luciferase reporter gene. Luciferase activity determined in cell
extracts increased upon AZA and/or TSA treatment and,
strikingly, even further upon addition of troglitazone, a specific
PPARc ligand (Figure S3). To demonstrate that the increase in
luciferase activity was really dependent upon the re-activated
receptor, we exposed the transfected cells to the PPARc
antagonist, GW9662. A significant reduction of reporter gene
activity was observed due to GW9662 ability to irreversibly
interfere with the transactivating ability of the mature protein
(Figure S3). All together these data show that DNA promoter
methylation and histone modifications likely co-operate to down-
regulate PPARG expression, suggesting that epigenetic treatments
re-establish gene transcription and activity.
Specific repressive chromatin marks and DNA
methylation are associated with PPARG transcription
To provide insights into the mechanism(s) by which DNA
methylation and histone modifications affect PPARG expression,
quantitative ChIP assays were performed investigating the
promoter segment extending from 2368 to 2166 in HCT116
cells. Consistent with the MeDIP data, HDAC1 was tightly bound
to PPARG promoter, whereas RNA-Polymerase II (RNAPol-II)
and its phosphorylated form (P-RNAPol-II) were barely present in
untreated HCT116 cells (Figure 3, panel A). Upon exposure to
AZA and TSA in combination, HDAC1 was remarkably depleted
along with a reduced DNA methylation (Figure S2), whereas
RNAPol-II and P-RNAPol-II were greatly enhanced, indicating
transcription recovering (Figure 3, panel A). Accordingly,
trimethylated H3K4 and acetylated H3K9, that are histone
modifications normally associated with transcriptional activity,
were almost reduced in untreated HCT116 cells and significantly
increased with TSA, AZA or their combination (Figure 3, panel
B). Of note, trimethylated H3K9, a marker of silenced chromatin,
was enriched at the PPARG promoter and progressively depleted
after epigenetic treatments, while trimethylated H3K27 was
significantly reduced only by the AZA/TSA combined treatment
(Figure 3, panel C). This analysis suggests that DNA
methylation is closely associated with repressive chromatin marks
at the PPARG promoter to impair gene expression in CRC cells.
siRNA mediated knock-down of MeCP2 and EZH2 rescues
PPARG expression in HCT116 colon cancer cells
The link between DNA methylation and histone modifications
appears to be mediated by a group of proteins with methyl DNA
binding activity that includes methyl CpG binding protein 2
(MeCP2) [14]. These proteins localize to methylated promoter
regions and recruit protein complexes containing HDACs,
especially HDAC1, and histone methyltransferases (HMTs).
Enhancer of zeste 2 (EZH2) is a member of the polycomb
repressor complex 2 (PRC2) with histone methyl-transferase
activity at specific H3K27 sites [21]. Both MeCP2 and EZH2
have been reported to be involved in Pparg repression in mouse
stellate cells undergoing liver fibrogenesis [22]. PPARG transcrip-
tional activation, on the other hand, appears to be modulated by
the zinc-finger protein (ZAC) likely together with other still
unknown factors [23]. MeCP2, EZH2 and HDAC1 were more
expressed in HCT116 than HT29 cells, thus inversely correlating
with PPARc, whereas ZAC levels directly associated with PPARc
(Figure 4, panels A and B and Figure S4). In line with this,
ChIP analysis showed that ZAC was more recruited in HT29 than
HCT116 cells. (Figure 4, panel B). Importantly, in PPARG-
negative cells following epigenetic treatment, ZAC became highly
enriched at the promoter correlating with PPARG transcription
recovery (Figure 4, panel B). ChIP assays performed in the same
setting showed that MeCP2 was highly recruited at the PPARG
promoter in basal conditions and depleted after treatment with
AZA or TSA alone or in combination (Figure 4, panel C).
Accordingly, silencing MeCP2 caused a marked increase of
PPARG expression (Figure 4, panel D). In the same HTC116
cells, the PPARG promoter was particularly enriched in
H3K27me3 (Figure 4, panel E). Knocking-down EZH2
associated with a three-fold increase of PPARc and reduction of
H3K27me3 at the PPARG promoter as compared with control
cells (Figure 4, panel F). Finally, MeCP2, HDAC1 and EZH2
levels were examined in a subset of CRCs. HDAC1 and EZH2
levels were more expressed in tumour tissues than the paired
normal mucosas and directly correlated with advanced Duke’s
stages (Figure S4). MeCP2, in contrast, was unchanged or slightly
increased in the same subset of tumours (Figure S4). Altogether
these results indicate that MeCP2, HDAC1 and EZH2 are
involved in PPARG repression in colon tumorigenesis both in vivo
and in vitro.
PPARG silencing is associated with an increased growth
rate and higher invasiveness of CRC cells
PPARc seems to play a role in cell proliferation and invasiveness
[6,24]. To investigate whether CRC cells growth and invasiveness
correlate with PPARc levels, we compared the HCT116 and
HT29 proliferation index. HCT116 showed a proliferation rate
two-fold higher than HT29 cells (Figure 5, panel A). We also
expression levels in the absence=M0 or presence=M1 of distant metastases. (C) Kaplan Meier survival analysis related to PPARG expression levels.
The P value is reported in each graph. (D) Schematic structure of the PPARG promoter and identification of the CpG-enriched regions encompassing
the transcription start site of the human gene. The MS-PCR regions analyzed (M1–M4) and the positions of the primers used are depicted as
rectangles. (E) Representative MS-PCRs show a correlation between methylation of the M3 region and reduced PPARG expression in tumour tissues
vs. matched normal mucosa, C+ indicates methylated (M) and unmethylated (U) controls. (F) The M3 nucleotide sequence is reported; the CpG
islands are highlighted. The chromatograms show which CpG dinucleotide is methylated in some representative samples after BS. Black or white
circles indicate the methylated or unmethylated cytosines, respectively. (G) Methylation levels detected by BS in tumour and normal mucosa
specimens. The M3 region methylation is related to tumour’ stage (Duke’s from A to D) (H) and patients’ survival (I). The P value is reported in each
graph.
doi:10.1371/journal.pone.0014229.g001
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14229Figure 2. Promoter methylation is associated with reduced PPARG expression levels in CRC cell lines. (A) PPARG mRNA and protein
levels detected by RT-PCR ad western blot analysis in a panel of eight CRC cell lines. GAPDH and b-actin were used as controls, respectively. (B) MS-
PCR results obtained on the M1–M4 promoter regions analyzed; M, methylated; U, unmethylated; C+ indicates methylated and unmethylated
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performing the wound-healing and migration assays. Interestingly,
HCT116 showed a higher motility and invasive potential than
HT29 cells (Figure 5, panels B and C). To investigate whether
these HCT116 growth characteristics rely on PPARG expression,
we stably silenced PPARG in HT29 cells. Among the HT29 clones
tested for PPARc levels, the clone shPPARG displayed a reduction
of more than 60% than cells transfected with the empty vector or
with a vector carrying non-specific shRNA (Figure 5, panel D).
According to our hypothesis, the shPPARG clone showed a higher
cell proliferation index, lower apoptotic rate and increased
invasion potential than HT29 transfected with a non-specific
shRNA (Figure 5, panels E and F and Figure S4). Regarding
the apoptotic rate, administration of TZD had no effect on the
HT29 shPPARG clone, as compared to parental cells (Figure
S4). Furthermore, we generated HCT116 cells stably over-
expressing a transfected wild type PPARc (Figure 5, panel G).
Consistently, in the presence of TZD these clones were inhibited
in their growth and displayed a higher apoptotic index than the
parental cells transfected with an empty vector (Figure 5, panel
H and Figure S4). These clones showed also a reduced
invasiveness and increased E-cadherin expression than the
parental cells (Figure 5, panels G–I). Collectively these results
suggest that PPARG differential expression and a TZD-dependent
activity accounts for the different growth and motility properties of
the CRC cell lines analyzed.
Discussion
Colorectal cancer is one of the most frequent malignancies in
western countries and the third most common cause of cancer-
related death worldwide [10,13]. Among genetic alterations,
chromosomal and microsatellite instability (CIN and MSI) have
been invoked in CRC tumorigenesis. Several lines of evidence
suggest that also epigenetic modifications contribute to the
establishment and/or to the progression of a tumour [12,13].
DNA hypermethylation is the most common epigenetic change
observed in human cancers, particularly in CRC, where it is
associated with TSGs silencing [12,13]. In colorectal tumorigen-
esis, the precise role played by PPARG has been questioned
because of the conflicting results reported [4–10]. PPARG
mutations alone do not fully explain the frequent variations in
expression detected in tumours [9,10,25]. Here, we provide
evidence that epigenetic alterations at the PPARG promoter are
related with gene repression that occurs in 30% of CRCs.
Dissecting the PPARG proximal promoter, we demonstrate that a
specific DNA segment (M3) is differentially methylated and
PPARG expression is directly correlated with its methylation status
(Figs. 1 and 2). Consistent with this observation, only 8% of the
paired normal mucosa is methylated in the same region, probably
due to the so-called ‘‘field defect’’ [13]. An association with
patients’ age at diagnosis was observed also in our CRC samples.
We also demonstrate that a reduced PPARG expression due to
specific promoter methylation is associated with advanced tumour
stages (Duke’s stages C–D), deep invasion, and, ultimately, shorter
survival. Other molecular alterations such as KRAS and BRAF
mutations do not seem to be associated with PPARG methylation,
while a correlation with the microsatellite instability status was
found (Figure S1) [10]. These data imply that PPARG promoter
methylation could be associated with CRC progression, providing
a molecular basis to our previous data and to a recent proposal of
PPARG as a favourable prognostic marker for CRC survival
[9,10]. It is poorly understood whether other genetic and
epigenetic events contribute not only to PPARG silencing but also
to overexpression detected in about 60% of CRCs. Likewise it is
not clear whether this epigenetic change is a cause or a
consequence of tumor progression. A subset of CRCs character-
ized by wide-spread methylation at CpG islands in the promoter
regions of several genes is recognized as CIMP. This group
appears not to be directly correlated with PPARG hypermethyla-
tion (our unpublished data), suggesting that methylation at this
specifc gene promoter is not caused by an aberrant spread of
methylation over extended genomic regions. Consistently, LINE
methylation levels, a surrogate marker of global DNA methylation,
does not correlate with PPARG expression in CRC [10]. It is worth
of note that methylation at the M3 segment of the PPARG
promoter occurs not only in tumours in vivo but also in CRC
derived cell lines. This is the first report that shows promoter
methylation to play a role in PPARG repression in tumorigenesis.
The only analysis reported so far, refers to the Pparg2 promoter in
a mouse model of diabetes related to the adult metabolic syndrome
[26]. The results obtained in 3T3-L1 preadipocytes and extended
to the human gene, for structure and sequence similarities, suggest
that also PPARG2 is regulated by DNA methylation [26]. More
recently, epigenetic regulation of Pparg has been invoked as an
important step in mouse myofibroblast transdifferentiation of
hepatic stellate cells that promotes liver fibrogenesis [22].
The link between DNA methylation and histone modifications
is mediated by a group of proteins with methyl-CpG-binding
activity. MeCP2 recruits co-repressor complexes including
HDACs and HMTs [27]. Its role in tumorigenesis is, however,
still debated [22,27,28]. EZH2 is also recruited and appears to be
involved in the maintenance of the repressed status [21]. Both
MeCP2 and EZH2 have recently been shown to be key regulators
of Pparg repression [22]. Consistently, MeCP2 and EZH2 levels
inversely correlate with PPARG expression in the CRC cells
investigated. In the silenced state, as in PPARG-negative HCT116
cells, the promoter is significantly enriched in HDAC1, MeCP2
and chromatin repressive marks such as H3K9me3 and
H3K27me3. This latter suggests the presence of EZH2-containing
repressive complexes. Differently, exposure to AZA and TSA
causes replacement with active chromatin marks such as H3K9Ac
and H3K4me3, accompanied by a complete loss of HDAC1 and
MeCP2. Recruitment of RNAPol-II and P-RNAPol-II under these
conditions fully correlates with the ability of the newly synthesized
receptor to transactivate a reporter gene. MeCP2 and EZH2
silencing re-activate PPARc, confirming their crucial role in
PPARG epigenetic repression. These conclusions are supported by
the enhanced growth properties of HT29 cells carrying a silenced
PPARG and by the reduced growth rate and migration properties
of HCT116 over-expressing a transfected wild type PPARc.
Collectively these functional analyses suggest that PPARG silencing
may actively contribute to colon tumor progression. Thus, we
propose a novel regulatory model in which an unmethylated (or
partially methylated) PPARG core promoter region is normally
controls. The methylation status of all CRC cell lines analyzed is summarized, with HCT116 and HT29 cells depicted in grey. (C) CpG dinucleotides
methylation was assessed by BS. The results of some representative cell lines are reported. Methylated or unmethylated CpG dinucleotides are
depicted as black or white circles, respectively. (D) Pharmacologic demethylation induced PPARG expression in HCT116 while no significant difference
was found in HT29 cells used as control. Cells were exposed to 1 and 5 mM AZA for 72 hs, MS-PCR was carried out on the M2 and M3 regions, before
and after treatment, **P,0.01.
doi:10.1371/journal.pone.0014229.g002
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14229Figure 3. PPARG transcriptional repression is due to specific repressive chromatin marks and recruitment of HDAC1. (A) Quantitative
ChIP analysis in HCT116 cells was performed before and after the treatment with AZA and TSA alone or in combination. Native chromatin was
incubated with antibodies directed against the indicated proteins. The immunoprecipitated DNA was used as template in qPCR reactions using
specific primers for the PPARG promoter region *P,0.05, **P,0.01. (B) ChIP assays were carried out as described above against acetylated H3K9 and
trimethylated H3K4 *P,0.05, **P,0.01 or (C) trimethylated H3K9 and H3K27 *P,0.05. The time-points for co-treatments were 72 hs for 5 mM AZA
and 24 hs for 300 nM TSA, alone or in combination; CC indicates untreated control cells. Results are the mean values 6 SD of three independent
experiments, each performed in duplicate.
doi:10.1371/journal.pone.0014229.g003
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PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14229Figure 4. MeCP2 and EZH2 are negative regulators of PPARG expression in CRC cell lines. (A) Western-blot analysis shows higher levels of MeCP2
andEZH2inHCT116thanHT29cells*P,0.01. (B)Inc ont ra st,Z ACismo reex pre ssedinHT 29tha nHC T116cells, thus directly correlatingwithPPARclevels. ChIP
assays performed in basal conditions show a ZAC enrichment in HT29 cells. In HCT116, ZAC is highly recruited at the PPARG promoter after epigenetic
treatments correlating with PPARG transcription recovery *P,0.05; **P=0.004; ***P=0.0001. (C) qChIP analysis shows enrichment of MeCP2 at the PPARG
promoter that is lost after pharmacological treatments. (D) A specific MeCP2-siRNA transfected into HCT116 cells determines complete silencing of its own
gene and PPARc re-expression, as assessed by Western blot, relatively to controls *P=0.01. (E) qChIP analysis shows that trimethylated H3K27 is enriched in
HCT116 as compared to HT29 cells. After AZA/TSA addition, H3K27 is unchanged in HT29 and reduced in HCT116 cells *P,0.05. (F) A specific EZH2-shRNA
introduced in HCT116 efficiently silences its own gene and induces PPARc expression, as illustrated by Western-blot analysis. This coincides with reduced
H3K27me3 levels analyzed by qChIP. *P,0.05. The time-points for co-treatments were 72 hs for 5 mM AZA and 24 hs for 300 nM TSA, alone or in combination;
CC indicates untreated control cells. Error bars indicate the standard deviation of the mean.
doi:10.1371/journal.pone.0014229.g004
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PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14229Figure 5. PPARG silencing increases proliferation and migration/invasiveness of CRC cells. (A) MTT assays on HCT116 and HT29 cells were carried
out at different time-points *P=0.004; **P=0.001. (B) A wound-healing migration assay was carried out comparing and measuring the ‘‘wound area’’ at 24 and
48 hs *P=0.045; **P=0.0051; ***P=0.0001. (C) Transwell migration assay was performed counting the run-through cells in 10 microscopic fields *P=0.024;
**P,0.01. The symbols represent the mean values of three independent experiments (mean 6 SD). (D)S p e c i f i cPPARG- or scrambled-shRNAs were stably
transfected into HT29 cells to generate the shPPARG or control clones, respectively; the extent of PPARc knock-down was documented by Western blot and
referred to b-actin. (E) shPPARG cells showed higher proliferation than control clones and parental cells *P=0.022; **P=0.012. (F) The wound-healing
migration and transwell migration assays were performed on the HT29 parental, the shPPARG and the control clone, respectively. The measurements were
done as above. In both cases, cells were fixed after 48 hs and stained with hematoxylin & eosin or crystal violet, respectively. Magnification: 1006.
Quantification of the wound-area after 24 and 48 hs is reported in the histogram where the control was set at 100%, *P=0.016,**P=0.001. Bars represent
mean values 6SDof three independent experiments. (G) HCT116 cells were stably transfected with an empty expression vector or a vector carrying the PPARc
cDNA to generate control or the HCT116-PPARcclones, respectively. Western blot analysis of the transfected PPARcand activated target E-cadherin referred to
b-actin. (H) The HCT116-PPARccells showed lower proliferation than control clones and parental cells in the presence of TZD *P=0.012. (I) The wound-healing
migration assay in HCT116 parental, the HCT116-PPARcand the control clone. Cells were fixed after 48 hs and stained with hematoxylin & eosin. Magnification:
1006. The histogram shows quantification of the wound-area, measured as above, with the control set at 100%. Bars represent mean values 6 SD of three
independent experiments *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0014229.g005
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only the zinc-finger protein ZAC has been identified so far in CRC
cells [23]. Upon promoter methylation, HDAC1 and MeCP2
repressive complexes are recruited to form a condensed chromatin
structure that suppresses transcription initiation. In this context,
EZH2-containing repressive complexes are further recruited, fully
‘‘marking’’ the histones via H3K27 methylation to establish a
stable PPARG silencing by blocking transcription elongation
(Figure 6). PPARG has been shown to potentiate the effects of a
variety of chemotherapeutic regimens on the assumption that the
addition of a specific ligand would render the receptor more
efficient in transactivating target genes [29]. Only few evidences in
the literature support the notion of adding a specific PPARc
agonist to well-established chemotherapeutic regimens for the
treatment of PPARG-positive CRCs [30]. On the basis of our data,
it is tempting to speculate a possible intervention for the treatment
of PPARG-negative CRCs, based on the combination of a
conventional chemotherapy with epigenetic drugs and a specific
PPARc agonist [31]. This regimen would re-establish PPARc
expression and activity, sensitize the tumour to the therapy,
overcome possible resistance to the agonist and result in a better
outcome with possibly longer survival.
In conclusion, we demonstrate that epigenetic events play a role
in PPARG expression. DNA methylation and the associated
chromatin repressive marks are responsible for PPARG silencing
in a proportion of sporadic CRCs and derived cell lines. Larger
epidemiological studies are required to support this hypothesis and
to translate these results into clinical practice.
Supporting Information
Figure S1 Correlation between K-RAS and B-RAF mutations,
microsatellite instability and PPARG methylation in CRCs. A
subset of our colorectal cancer series was analyzed for K-RAS
mutations at codons 12, 13 and B-RAF mutation at codon 600.
CRCs were stratified based on Microsatellite stability (MSS) or
instability (MSI) and related to PPARG methylation status (in
grey).
Found at: doi:10.1371/journal.pone.0014229.s001 (2.85 MB TIF)
Figure S2 Loss of PPARG expression in CRC cell lines is due to
DNA promoter methylation. (A) PPARG Loss Of Heterozigosity
(LOH) was tested in HCT116 and HT29 cells using two DNA
markers flanking the PPARG locus at the 59 and 39 end,
respectively. No differences were appreciated, indicating that the
locus had not been rearranged. Size marker=SM. (B) Activation
of the MAPK/ERK signalling pathway did not correlate with the
loss of PPARG expression. Basal and phosphorylated ERK levels
were lower in PPARG-negative HCT116 than in PPARG-positive
HT29 cells. (C) Quantitative ChIP analysis demonstrated
enrichment of 5-methyl-cytosine (5-MeC) at the PPARG promoter
in HCT116 with respect to HT29 cells. Epigenetic treatment
significantly reduced 5-methyl-cytosine only in HCT116 cells
*P,0.01. Error bars indicate the standard deviation of the mean.
Found at: doi:10.1371/journal.pone.0014229.s002 (1.90 MB TIF)
Figure S3 Synergistic effect of AZA and Trichostatin A (TSA)
on PPARG re-activation. (A) HCT116 were treated with 1- 5 mM
AZA for 72 hs, with 300 nM TSA for 24 hs alone or in
combination with 1 or 5 mM AZA. HT29 cells served as control.
PPARc levels were analyzed by western-blot and quantified
referring to b-actin. The histograms show that AZA/TSA in
combination induce a synergistic PPARG re-activation only in
HCT116 cells *P,0.05, **P,0.01, ***P=0.0001, whereas no
significant differences were observed in treated HT29 as compared
to untreated control cells. (B) To confirm the synergistic effect on
PPARc activity, HCT116 were treated with AZA and TSA alone
or in combination and transiently transfected with the PPRE-TK-
luciferase reporter gene. After twelve hours the cells were treated
with 1mM TZD or GW9662, a selective antagonist, or the vehicle
alone (V). TZD administration increased the luciferase reporter
gene activity, while exposure to GW9662 drastically reduced it
even if compared with the vehicle alone. Luciferase activity was
determined and normalized to b-galactosidase for transfection
efficiency. Results are the mean values 6 SD of three independent
experiments, each performed in duplicate and compared with the
corresponding controls; CC indicates untreated control cells
*P,0.01; **P=0.002.
Found at: doi:10.1371/journal.pone.0014229.s003 (2.61 MB TIF)
Figure S4 HDAC1, MeCP2 and EZH2 expression levels in
CRCs samples and cell lines. (A) Western blot analysis for HDAC1
was carried out in HCT116 and in the indicated CRC cell lines.
(B) Protein extracts from representative tumour tissues (T) and
Figure 6 Schematic drawing of the proposed molecular mechanism(s) of PPARG silencing. (I) The unmethylated or partially methylated
PPARG core promoter is activated by unknown transcriptional factors, among which only the zinc-finger protein ZAC that induces apoptosis and cell-
cycle arrest has been identified. (II) Upon extensive promoter DNA methylation, MeCP2, HDAC1 and EZH2 containing repressive complexes are
recruited to form a condensed chromatin structure, inhibiting RNA polymerase II and impairing gene transcription.
doi:10.1371/journal.pone.0014229.g006
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EZH2 and MeCP2. b-actin was used as internal control in both
cases. (C) Immunohistochemical analysis of some representative
tumour samples expressing high and low HDAC1 and PPARc
levels, respectively. (D) HDAC1, EZH2 and MeCP2 expression
levels in a subset of CRCs (N=20) and paired normal mucosa are
represented by box-plot. The edges of the boxes are the
interquartile range box, lines in the boxes represent the median
value; the P value in each graph was obtained by the Mann-
Whitney test (E). In some representative tumour samples (n=52),
HDAC1 and EZH2 high expression was directly related with C-D
Duke’s tumour stages. The same relationship was not found for
MeCP2. P value was calculated by the Spearman correlation. (F)
To assess the apoptotic rate induced by the PPARc ligand
troglitazone (TZD), flow cytometrical analysis (FCA) was carried
out in HT29 parental cells transfected with a control plasmid (CC)
or with an shPPARG. Alternatively, FCA was performed in
HCT116 transfected with an empty vector (EV) or with an
expression vector for PPARc HCT116+PPARGc.
Found at: doi:10.1371/journal.pone.0014229.s004 (1.24 MB
PDF)
Table S1
Found at: doi:10.1371/journal.pone.0014229.s005 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0014229.s006 (0.04 MB
DOC)
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